PMID- 23526065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 2
IP  - 2
DP  - 2013 Feb 1
TI  - Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells 
      against breast cancer.
PG  - e23335
LID - e23335
AB  - Dendritic cells (DCs) are among the most potent antigen-presenting cells (APCs), 
      stimulating peripheral blood mononuclear cells (PBMCs) to generate 
      antigen-specific cytotoxic T lymphocytes (CTLs). The objectives of this study 
      were to determine if interleukin (IL)-4 is beneficial or detrimental for the 
      generation of human DCs in vitro and to understand whether DCs generated in vitro 
      in the presence or absence of IL-4 stimulate the killing of adenocarcinoma cells 
      by CTLs in vivo. Mucin 1 (MUC1), a glycoprotein found on the surface of 
      adenocarcinoma cells was used to load DCs. MUC1-loaded DCs generated in the 
      absence of IL-4 were superior to their counterparts produced with IL-4 in 
      stimulating PBMCs to kill human breast cancer MCF-7 cells in vitro. A corollary 
      in vivo protection experiment was performed by injecting immunodeficient NOD-SCID 
      mice with MCF-7 cells s.c. and MUC1-loaded CTLs, PBMCs, or DCs generated in the 
      absence of IL-4, i.p. Mice that received CTLs and MUC1-loaded DCs on days 0, 2, 
      4, 9, 14 and 19 were completely protected against the development of 
      MCF-7-derived tumors, while other schedules conferred lower protection. 
      Therefore, tumor antigen-loaded DCs enhance the efficacy of adoptive CTL 
      transfer, and should thus be considered for combinatorial immunotherapeutic 
      regimens.
FAU - Wang, Zhenyao
AU  - Wang Z
AD  - Departments of Internal Medicine and Biomedical Sciences; Texas Tech University 
      Health Sciences Center Schools of Medicine and Pharmacy; Amarillo, TX USA ; 
      Department of Life, Earth and Environmental Sciences; West Texas A & M 
      University; Canyon, TX USA.
FAU - Hall, Monte D
AU  - Hall MD
FAU - Rewers-Felkins, Kathleen A
AU  - Rewers-Felkins KA
FAU - Quinlin, Imelda S
AU  - Quinlin IS
FAU - Wright, Stephen E
AU  - Wright SE
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC3601184
OTO - NOTNLM
OT  - cytotoxic cells
OT  - dendritic cells
OT  - immunotherapy
OT  - protection
EDAT- 2013/03/26 06:00
MHDA- 2013/03/26 06:01
PMCR- 2013/02/01
CRDT- 2013/03/26 06:00
PHST- 2013/03/26 06:00 [entrez]
PHST- 2013/03/26 06:00 [pubmed]
PHST- 2013/03/26 06:01 [medline]
PHST- 2013/02/01 00:00 [pmc-release]
AID - 2012ONCOIMM0348R [pii]
AID - 10.4161/onci.23335 [doi]
PST - ppublish
SO  - Oncoimmunology. 2013 Feb 1;2(2):e23335. doi: 10.4161/onci.23335.